Vantia Therapeutics Completes Enrollment in the EQUINOC® Study, a Pivotal Study with Fedovapagon for the Treatment of Nocturia in Men with Benign Prostatic Hyperplasia

Southampton, UK, 11 April 2017 – Vantia Therapeutics announces it has completed enrolment in the EQUINOC® Study, pivotal clinical study to investigate the efficacy and safety of fedovapagon (VA106483) in the treatment of nocturia in men with benign prostatic hyperplasia (BPH) (the "EQUINOC" study).

EQUINOC is a randomised, double-blind, placebo-controlled, multi-centre study. 432 patients were enrolled in the study in the United States. Patients were randomised to receive fedovapagon or placebo each evening over a 12-week treatment period. The co-primary efficacy endpoints are reduction in the mean number of night-time voids (waking and urinating) and change in the NocTIMe®, a patient reported outcome score. Vantia developed the NocTIMe® specifically to assess the effect of treatment on the quality of life of nocturia patients. Preliminary results and analysis are expected in the third quarter of 2017.

"The completion of enrolment in the EQUINOC study is an important milestone in our development of fedovapagon for nocturia," said Hilary McElwaine-Johnn, Chief Medical Officer of Vantia. "We look forward to the availability of top-line data from the study, which we expect in the third quarter of this year. We are grateful for the participation of patients and investigators in our ongoing clinical trial program,."

Nocturia is a common condition that causes sufferers to wake frequently during the night in order to urinate ("nocturnal or night-time voids"). Its prevalence and severity increases markedly with age and it is often the presenting symptom in men with BPH (enlarged prostate gland), affecting at least 70% of BPH patients. Nocturia has a significant detrimental impact on the quality of life in patients. Current treatment options are limited for a market estimated at more than US$1 billion.

Fedovapagon is a selective, small molecule vasopressin V2 receptor agonist, discovered by Vantia scientists, that has an anti-diuretic effect through stimulation of V2 receptors in the kidney. Preliminary efficacy and safety of fedovapagon, and a dose for the EQUINOC trial, has been established in several completed clinical studies.

Contact details:

Vantia Therapeutics
Stephen Donnelly

+44 (0)238 076 3456 /+44 (0)787 255 9676
info@vantia.com

Citigate Dewe Rogerson
Mark Swallow

+44 (0)207 638 9571
vantia@citigatedr.co.uk

About Vantia Therapeutics:

Vantia Therapeutics is an emerging pharmaceutical company developing novel, small molecule drugs targeting large areas of unmet medical need. Its lead clinical candidate, fedovapagon (VA106483), was discovered by Vantia scientists and is in a pivotal clinical study for the treatment of nocturia in men with benign prostatic hyperplasia (BPH). The Company was founded in 2008 and is backed by specialist life science investors Novo A/S, SV Life Sciences and MVM Life Science Partners.
www.vantia.com